Stock Analiz

Sanofi (SNY) financials: revenue, earnings and cash flow

Fiscal 2016–2025 + TTM · from SEC filings · data as of November 16, 2026

Summary

Sanofi’s revenue went from $35.6B in fiscal 2016 to $51.3B in fiscal 2025, growth of about 4.1% a year.

Net income in fiscal 2025 was $9.2B, a net margin of 17.9%; the best year in this period was 2020 with $15.1B.

Over the twelve months to September 30, 2026, revenue was $56.2B and net income $4.6B.

Free cash flow was $8.5B in fiscal 2025 and positive in 7 of the 10 years shown.

Revenue, profit and cash flow by year

Revenue
2016: $35.6B162017: $42.1B172018: $39.5B182019: $40.6B192020: $44.2B202021: $42.8B212022: $40.2B222023: $41.8B232024: $42.7B242025: $51.3B25$51.3B
Net income
2016: $5.0B162017: $10.1B172018: $4.9B182019: $3.1B192020: $15.1B202021: $7.0B212022: $8.9B222023: $6.0B232024: $5.8B242025: $9.2B25$9.2B
Free cash flow
2019: $6.7B20192020: $6.5B20202021: $9.6B20212022: $9.0B20222023: $8.1B20232024: $6.1B20242025: $8.5B2025$8.5B
EPS (diluted)
2016: $2.04162017: $4.14172018: $2.02182019: $1.27192020: $6.19202021: $2.89212022: $3.66222023: $2.45232024: $2.37242025: $3.7625$3.76

Income statement

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$56.2B$51.3B$42.7B$41.8B$40.2B$42.8B$44.2B$40.6B$39.5B$42.1B$35.6B
Gross profit—$39.6B$32.3B$32.0B$30.6B$30.5B$30.9B$28.8B$27.8B$29.5B$25.3B
Operating income—$7.5B$7.5B$7.7B$10.8B$9.2B$17.3B$3.4B$5.4B$7.0B$6.9B
Net income$4.6B$9.2B$5.8B$6.0B$8.9B$7.0B$15.1B$3.1B$4.9B$10.1B$5.0B
EPS (diluted)$1.91$3.76$2.37$2.45$3.66$2.89$6.19$1.27$2.02$4.14$2.04
R&D———————————
Revenue growth—+20.1%+2.1%+4.1%−6.1%−3.3%+9.0%+2.9%−6.2%+18.0%−3.9%

Cash flow

Fiscal yearTTM2025202420232022202120202019201820172016
Operating cash flow$13.2B$12.6B$9.4B$11.3B$11.2B$11.9B$9.1B$8.7B$6.4B$8.8B$8.3B
Capital spending-$3.1B-$4.2B-$3.3B-$3.2B-$2.2B-$2.3B-$2.6B-$2.0B———
Free cash flow$9.3B$8.5B$6.1B$8.1B$9.0B$9.6B$6.5B$6.7B———
Dividends paid$5.3B$5.6B$4.9B$4.9B$4.4B$4.5B$4.8B$4.3B$4.3B$4.4B$4.0B
Buybacks—$5.9B$314M$655M$530M$433M$1.0B$10M$1.3B$2.6B$3.1B
Stock-based pay—$368M$289M$287M$250M$276M$336M$283M$325M$315M$254M

Balance sheet

Fiscal yearTTM2025202420232022202120202019201820172016
Cash—$9.0B$7.7B$9.6B$13.6B$11.4B$17.1B$10.6B$7.9B$12.4B$10.8B
Debt—$22.0B$16.8B$18.3B$20.5B$23.0B$27.8B$27.7B$28.2B$18.7B$19.6B
Equity—$83.9B$80.5B$81.8B$79.8B$77.8B$77.4B$66.3B$67.4B$69.6B$60.7B
Total assets—$149.0B$138.0B$139.7B$135.2B$136.2B$140.4B$126.5B$127.6B$119.7B$110.3B
Shares (diluted)2.41B2.44B2.44B2.44B2.44B2.44B2.44B2.44B2.44B2.44B2.44B

Margins and returns

Fiscal yearTTM2025202420232022202120202019201820172016
Gross margin—77.2%75.7%76.7%76.2%71.3%70.0%71.0%70.3%70.2%71.0%
Operating margin—14.5%17.6%18.4%27.0%21.5%39.2%8.5%13.6%16.6%19.3%
Net margin8.2%17.9%13.5%14.3%22.2%16.5%34.1%7.6%12.5%24.0%13.9%
FCF margin16.5%16.5%14.3%19.4%22.4%22.4%14.8%16.4%———
ROIC—5.6%6.1%6.1%8.5%7.2%13.0%2.9%4.4%6.2%6.8%
ROE—10.9%7.2%7.3%11.2%9.1%19.5%4.7%7.3%14.5%8.2%

Frequently asked questions

What is Sanofi’s annual revenue?

$51.3B in fiscal 2025 and $56.2B over the twelve months to September 30, 2026.

How much profit does Sanofi make?

Net income was $9.2B in fiscal 2025 (net margin 17.9%).

Is Sanofi’s revenue growing?

Yes: revenue rose 20.1% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.